Organ-on-a-chip technology is still in its early stages of development, and the pharmaceutical sector is actively testing and evaluating it. OOC makers must be able to demonstrate and give similar quality data of OOCs with existing animal studies for the aim of safety evaluation to move on from animal research. Based on the data, the food and drug administration can determine whether such a shift is feasible. The technology is still in its early stages, and there isn't enough proof to back up its real-time applications. In this article, we are going to discuss the leading market players that are engaged in the Organ on a Chip market.